Month: January 2023

PHOENIX, Jan. 12, 2023 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT” or the “Company”) (NEO: TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, today announced its Chief Executive Officer (“CEO”) Gary Santo has been appointed to the Board of Directors of the National Cannabis Roundtable (“NCR”). Founded in 2019, NCR is a non-partisan alliance of cannabis companies and ancillary services and solutions providers working to advance cannabis policy in the United States. “The National Cannabis Roundtable has been and continues to be at the forefront of federal cannabis policy,” said Gary Santo, TILT’s CEO. “While the industry made some important gains, including a presidential pardon of all federal convictions...

BEDMINSTER, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced a strategic collaboration with National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines. The parties have entered into a Material Transfer and Evaluation Agreement focused on exploring the potential for oral delivery of identified nucleic acids. The parties will closely collaborate on a comprehensive research program comprising the design, formulation, optimization, and in vitro and in vivo testing of these nucleic acid formats in combination with Matinas’ proprietary LNC...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Jan. 12, 2023 (GLOBE NEWSWIRE) — C2C Gold Corp. (CSE: CTOC, OTCQB: CTCGF) (“C2C Gold” or the “Company”) announced today a non-brokered private placement of units (the “Units”) for aggregate gross proceeds of a minimum of $500,000 and up to maximum of $1.0 million at a price of C$0.05 per Unit (the “Offering”). Each Unit will consist of one common share in the capital of the Company and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant shall entitle the holder to acquire an additional common share at a price of $0.10 for a period of 24 months following the closing of the Offering. The Units will be offered by way of the “listed issuer” exemption under National Instrument...

VANCOUVER, British Columbia, Jan. 12, 2023 (GLOBE NEWSWIRE) — PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) (“PlantX” or the “Company”), the digital face of the plant-based community, operating a one-stop shop for plant-based products, today announced retaining a law firm to review and assess legal options against auditors. PlantX has identified concerns with the delay, preparation, and issuance of the restatement of its fiscal 2021 financial statements and the audit of its fiscal 2022 financial statements. PlantX has retained Kushneryk Morgan LLP to review and assess legal options, including seeking financial recovery, to address the harm caused by the delay, preparation, and issuance of those materials. PlantX will take appropriate legal action against those who are responsible. Kushneryk Morgan LLP is a boutique...

U.S. distribution agreement signed with GNC for Mikra’s flagship product CELLF, making GNC the exclusive distributor for U.S. retail stores and on Amazon at GNC’s channel TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. (“Mikra”) has signed a distribution agreement with GNC Holdings, LLC (“GNC”) to make GNC the exclusive distribution partner for CELLF and its future derivates in the United States in GNC’s retail stores, at gnc.com and on GNC’s channel on Amazon.com, for an initial 12-month period. GNC is one of the world’s...

Mobile app allows fleet owners and operators to manage the health and performance of their battery-electric fleets on the goXosphere Go™ mobile application 1 Available for iOS and Android devicesXosphere Go™ mobile application 2 Xosphere Go™ allows fleet owners to manage the health and performance of their electric fleet from the palm of their handXosphere Go™ mobile application 3 Make and access service requests and assess the real-time health of your fleet with Xosphere GoLOS ANGELES, Jan. 12, 2023 (GLOBE NEWSWIRE) — Xos, Inc. (NASDAQ: XOS), a leading technology company which provides fleet services, software solutions, and manufactures Class 5 through Class 8 battery-electric commercial vehicles, today announced it has launched its mobile fleet management application, Xosphere Go™,...

NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) — Jack Creek Investment Corp. (“Jack Creek”) (Nasdaq: JCIC), a Cayman Islands exempted company, today announced the rescheduling of Jack Creek’s extraordinary general meeting of shareholders (the “EGM”) previously scheduled to be held on January 12, 2023. The EGM has been rescheduled for January 24, 2023 at 10:00 a.m. Eastern Time. The deadline for holders of Class A ordinary shares to request that Jack Creek redeem all or a portion of their shares is, accordingly, January 20, 2023 at 5:00 p.m. Eastern Time. As previously announced, the EGM will occur at the offices of Weil, Gotshal & Manges LLP located at 767 Fifth Avenue, New York, NY 10153 and virtually via live webcast at https://www.cstproxy.com/jackcreekinvestmentcorp/2023. The EGM is being held to vote on the proposals described...

STOCKHOLM, SWEDEN, January 12, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has dosed the first patient in a clinical phase 1/2a study of the drug candidate ATRN-119, which is being evaluated as a treatment for advanced solid tumors by affecting a signaling pathway important for tumor DNA repair. The phase 1/2a clinical trial is a multi-center, open-label, dose-escalation and expansion study designed to test ATRN-119 monotherapy in patients with advanced solid tumors. The first part of the study will evaluate tolerability, pharmacokinetics, recommended phase 2 dose and analysis of patient biomarkers. The Phase 2a expansion part of the trial is designed to further evaluate the tolerability and efficacy of ATRN-119 as a monotherapy. Results from the study will be presented...